Sep 22, 2026, 3:46 PMBiotechnology
Viking Therapeutics Stock Soars as Monthly VK2735 Dosing Maintains Weight Loss
Viking Therapeutics’ VK2735 maintained weight loss in a clinical trial, including with monthly dosing, as it targets Eli Lilly’s Zepbound in the market.
Listen to this briefingAudio briefing
Summary
MarketWatch reported on September 22, 2026, that Viking Therapeutics’ investigational VK2735 helped clinical-trial participants maintain weight loss, including those receiving the drug once monthly. VK2735 targets both GLP-1 and GIP and is being developed to compete with Eli Lilly’s Zepbound.
Viking Therapeutics shares were soaring, although the limited feed summary provided no stock-price move, trial phase, participant count, efficacy measurements, safety results, dosing details beyond once-monthly use, or development timeline.
Positives
- VK2735 helped clinical-trial participants maintain their weight loss, according to MarketWatch.
- Once-monthly VK2735 recipients also maintained weight loss, extending the reported result to a less frequent dosing schedule.
- VK2735 targets both GLP-1 and GIP and is being developed as a potential Zepbound competitor.
- Viking Therapeutics stock was soaring when MarketWatch published the report.
Risks & concerns
- VK2735 remains in development, and the available summary does not report an approval or commercialization timeline.
- The limited feed disclosed no trial phase, participant count, efficacy measurements, statistical results, or safety findings.
- Eli Lilly’s Zepbound is the named competing drug, placing VK2735 against an established rival.
- The report quantified neither Viking Therapeutics’ share-price increase nor the clinical result’s magnitude.
Primary sourceMarketWatch.com - Top Storieshttps://www.marketwatch.com/story/this-glp-1-drug-helped-people-maintain-their-weight-loss-in-a-clinical-trial-even-for-those-taking-it-once-a-month-f70929b5?mod=mw_rss_topstories
Read full article
